ArticleJournal for immunotherapy of cancer2020

Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.